INSIGHTS ON CLINICAL TRIAL PARTNERING

• Multi-Site Capabilities For Your Phase I-II Trials

  Master the complexities of renal and hepatic trials by leveraging site expertise and PK modeling to navigate recruitment challenges and ensure precise dosing for impaired patient populations.

• De-Risking FIH: Integrated Strategies For Rapid Proof-Of-Concept

  Proper planning for first-in-human studies is crucial to successful drug development, which requires innovative trial designs and sound CMC strategies to mitigate risk and expedite proof-of-concept.

• Participant Payments Without Site Burden

  Participant payments can create extra work for clinical trial sites. Learn how clearer ownership, connected workflows, and direct support reduce site burden while preserving visibility.

• What Sites Really Want: Insights From The 2024 Site Landscape Survey

  Take a closer look at the 2024 SCRS Site Landscape Survey—and what sites say they need most. Less friction. More follow-through. And partners who actually lighten the load.

• What Sponsors Need To Know Before They Get To The IRB & IBC

  5/13/2026

  Gene therapy requires early, rigorous safety planning and command of pediatric and biosafety rules. Early committee engagement reduces delays and strengthens high‑stakes trials.

• Optimizing Chronic Cough Phase 3 Trials With Point-Of-Need Eye Assessments

  1/15/2025

  Collaboration was key for Company W to overcome challenges with an FDA-mandated ocular substudy, including limited resources for ocular assessments and logistical difficulties

• Why Trial Expertise Makes Or Breaks Clinical AI

  7/30/2026

  What makes AI effective in clinical trials? See how a top 5 pharma sponsor achieved a 62% reduction in CRA task time and 99% document classification accuracy by prioritizing clinical fluency.

• Go From Three Meetings To One With AI-Enabled eCOA

  5/5/2026

  Learn how to turn three meetings into one with AI that is streamlining clinical workflows by reducing redundant steps, simplifying site operations, and accelerating data collection.

• Targeted Protein Degraders: Transforming Oral Therapeutics

  8/11/2025

  CDMOs play a critical role in TPD development by offering specialized infrastructure and analytical capabilities to support the transition from preclinical research to clinical supply and commercialization.